What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
- PMID: 17017830
- DOI: 10.4088/jcp.v67n0914
What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
Abstract
Objective: Symptom-free remission is a goal for treatment in depression and anxiety disorders, but there is no consensus regarding the threshold for determining remission in individual disorders. We sought to determine these thresholds by comparing, in a post hoc analysis, scores on the Clinical Global Impressions scale (CGI) and disorder-specific symptom severity rating scales from all available studies of the treatment of major depressive disorder, panic disorder, generalized anxiety disorder, and social anxiety disorder with the same medication (escitalopram). We also sought to compare the standardized effect sizes of escitalopram for these 4 psychiatric disorders.
Data sources and study selection: Raw data from all randomized, double-blind, placebo-controlled, acute treatment studies sponsored by H. Lundbeck A/S (Copenhagen, Denmark) or Forest Laboratories, Inc. (New York, N.Y.), published through March 1, 2004, with patients treated with escitalopram for DSM-IV major depressive disorder (5 studies), panic disorder (1 study), generalized anxiety disorder (4 studies), or social anxiety disorder (2 studies) were compared with regard to the standardized effect sizes of change in CGI score and scores on rating scales that represent the "gold standard" for assessment of these disorders (the Montgomery-Asberg Depression Rating Scale, the Panic and Agoraphobia Scale, the Hamilton Rating Scale for Anxiety, and the Liebowitz Social Anxiety Scale, respectively).
Data synthesis: In all indications, treatment with escitalopram showed differences from placebo in treatment effect from 0.32 to 0.59 on the CGI-S and CGI-I and standardized effect sizes from 0.32 to 0.50 on the standard rating scales. There were no significant differences among the different disorders. Moderate to high correlations were found between scores on the CGI and the standard scales. The corresponding standard scale scores for CGI-defined "response" and "remission" were determined.
Conclusion: Comparison of scores on the standard scales and scores on the CGI suggest that the traditional definition of response (i.e., a 50% reduction in a standard scale) may be too conservative.
Similar articles
-
[Efficacy and tolerability of escitalopram in anxiety disorders: a review].Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Encephale. 2008. PMID: 18922243 Review. French.
-
Escitalopram : a review of its use in the management of major depressive and anxiety disorders.CNS Drugs. 2003;17(5):343-62. doi: 10.2165/00023210-200317050-00004. CNS Drugs. 2003. PMID: 12665392 Review.
-
Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.J Clin Psychiatry. 2010 Feb;71(2):121-9. doi: 10.4088/JCP.08m04749blu. Epub 2009 Dec 1. J Clin Psychiatry. 2010. PMID: 19961809
-
[Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].Encephale. 2004 Mar-Apr;30(2):158-66. doi: 10.1016/s0013-7006(04)95427-9. Encephale. 2004. PMID: 15107719 Clinical Trial. French.
-
Remission rates in patients with anxiety disorders treated with paroxetine.J Clin Psychiatry. 2004 Dec;65(12):1696-707. doi: 10.4088/jcp.v65n1216. J Clin Psychiatry. 2004. PMID: 15641876
Cited by
-
One Hundred Courses of Cluster Maintenance Transcranial Magnetic Stimulation (CM TMS)-A Clinical Audit Study.Psychopharmacol Bull. 2022 Oct 27;52(4):61-68. Psychopharmacol Bull. 2022. PMID: 36339276 Free PMC article.
-
Improving study design for antidepressant effectiveness assessment.Int J Methods Psychiatr Res. 2013 Sep;22(3):217-31. doi: 10.1002/mpr.1391. Epub 2013 Aug 30. Int J Methods Psychiatr Res. 2013. PMID: 24038333 Free PMC article.
-
Second Courses of Transcranial Magnetic Stimulation (TMS) in Major Depressive Episodes for Initial Responders and Non-Responders.Malays J Med Sci. 2019 May;26(3):102-109. doi: 10.21315/mjms2019.26.3.8. Epub 2019 Jun 28. Malays J Med Sci. 2019. PMID: 31303854 Free PMC article.
-
Can Long-Term Pharmacotherapy Prevent Relapses in Generalized Anxiety Disorder? A Systematic Review.Clin Drug Investig. 2017 Aug;37(8):737-743. doi: 10.1007/s40261-017-0528-x. Clin Drug Investig. 2017. PMID: 28432583
-
Treatment response, symptom remission, and wellness in obsessive-compulsive disorder.J Clin Psychiatry. 2013 Jul;74(7):685-90. doi: 10.4088/JCP.12m07789. J Clin Psychiatry. 2013. PMID: 23945445 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical